[
    [
        {
            "time": "2020-03-18",
            "original_text": "How Are Biotech ETFs Reacting to Coronavirus Treatment News?",
            "features": {
                "keywords": [
                    "biotech",
                    "ETFs",
                    "coronavirus",
                    "treatment"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Are Biotech ETFs Reacting to Coronavirus Treatment News?",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-06-10",
            "original_text": "Wednesday Morning Market Highlights",
            "features": {
                "keywords": [
                    "market",
                    "highlights"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Wednesday Morning Market Highlights",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-07-22",
            "original_text": "Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study",
            "features": {
                "keywords": [
                    "Bristol Myers",
                    "Zeposia",
                    "ulcerative colitis",
                    "study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-15",
            "original_text": "Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market",
            "features": {
                "keywords": [
                    "pharma",
                    "stocks",
                    "outperform"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-07",
            "original_text": "HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates",
            "features": {
                "keywords": [
                    "HealthEquity",
                    "earnings",
                    "revenues",
                    "miss estimates"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-06-05",
            "original_text": "EULAR 2020: Lilly Shares New Data for Olumiant速 in Rheumatoid Arthritis and Systemic Lupus Erythematosus",
            "features": {
                "keywords": [
                    "EULAR",
                    "Lilly",
                    "Olumiant",
                    "rheumatoid arthritis",
                    "systemic lupus erythematosus"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "EULAR 2020: Lilly Shares New Data for Olumiant速 in Rheumatoid Arthritis and Systemic Lupus Erythematosus",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-06-06",
            "original_text": "EULAR 2020: Lilly's Taltz速 (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis",
            "features": {
                "keywords": [
                    "EULAR",
                    "Lilly",
                    "Taltz",
                    "psoriatic arthritis",
                    "efficacy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "EULAR 2020: Lilly's Taltz速 (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-27",
            "original_text": "Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Regeneron",
                    "COVID-19",
                    "treatment"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]